Antengene Corporation Limited, a leading innovative commercial-stage global biotech company listed on the Hong Kong Stock Exchange (SEHK: 6996.HK), announced a significant regulatory milestone on December 17, 2025. The Malaysian National Pharmaceutical Regulatory Agency (NPRA) has approved the supplemental New Drug Application (sNDA) for XPOVIO® (selinexor), expanding its indications to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have undergone at least two lines of systemic therapy and are ineligible for autologous stem cell transplant. This approval marks a pivotal expansion in Antengene's hematology portfolio within the Asian market, specifically in Malaysia, bringing the total approved indications for XPOVIO® in the country to three across multiple myeloma (MM) and DLBCL—two critical therapeutic areas in hematological malignancies.[1]

Prior to this approval, XPOVIO® was authorized in Malaysia for two MM indications: first, in combination with bortezomib and dexamethasone for adults who have received at least one prior therapy; and second, in combination with dexamethasone for those who have received at least four prior therapies, with disease refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, demonstrating progression on the last therapy. The addition of the DLBCL indication broadens the drug's reach, offering a novel treatment option for a larger patient population in need of effective therapies post-multiple failures. XPOVIO®, the world's first orally available selective XPO1 inhibitor, operates via a unique mechanism of action that blocks nuclear export, thereby reactivating tumor suppressor pathways and inducing cancer cell death.[1]

This development underscores Antengene's strategic focus on advancing first-in-class and best-in-class medicines for unmet needs in autoimmune diseases, solid tumors, and hematological malignancies. To date, the company has secured 32 investigational new drug (IND) approvals across the U.S. and Asia, alongside new drug applications (NDAs) submitted in multiple Asia-Pacific markets. XPOVIO® is now approved in ten APAC countries and regions, including Mainland China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia. Notably, it has achieved national insurance reimbursement in five of these markets: Mainland China, Taiwan China, Australia, South Korea, and Singapore, with expectations for further coverage expansions.[1]

Antengene's robust pipeline extends beyond XPOVIO®, encompassing in-house discovered programs from preclinical to commercial stages. Key assets include ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor). This diverse portfolio positions Antengene as a key player in the global biotech landscape, particularly in Asia, where it leverages regional regulatory efficiencies and market access strategies to commercialize innovative therapies.[1]

The approval in Malaysia not only enhances patient access to advanced treatments but also reflects the growing harmonization of regulatory standards in APAC, facilitating faster drug approvals and market penetration. For pharmaceutical executives and R&D leaders, this event highlights the importance of supplemental indications in extending product lifecycles and maximizing commercial potential in emerging markets. It also signals Antengene's operational maturity in navigating complex sNDA processes, a critical competency for contract research organizations (CROs) and contract manufacturing organizations (CMOs) partnering with such biotechs.[1]

Looking ahead, Antengene anticipates broader insurance inclusions for XPOVIO® across additional APAC markets, potentially driving revenue growth and supporting further pipeline investments. This milestone aligns with broader trends in Asian pharmaceutical innovation, where regulatory agility and targeted therapies are reshaping hematology treatment paradigms. Stakeholders in pharmaceutical outsourcing, regulatory compliance, and market access should monitor Antengene's progress, as it exemplifies successful B2B strategies in biotech commercialization within the region.[1]

In summary, this approval reinforces Antengene's leadership in delivering impactful therapies, fostering strategic partnerships, and contributing to the economic development of Asia's biotech sector through sustained R&D and market expansion efforts.